PMID- 18087285
OWN - NLM
STAT- MEDLINE
DCOM- 20080327
LR  - 20230317
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 98
IP  - 2
DP  - 2008 Jan 29
TI  - Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 
      expression in cholangiocarcinoma.
PG  - 418-25
AB  - Epidermal growth factor receptor (EGFR), vascular endothelial growth factor 
      (VEGF), and human epidermal growth factor receptor 2 (HER2) have been considered 
      as potential therapeutic targets in cholangiocarcinoma, but no studies have yet 
      clarified the clinicopathological or prognostic significance of these molecules. 
      Immunohistochemical expression of these molecules was assessed retrospectively in 
      236 cases of cholangiocarcinoma, as well as associations between the expression 
      of these molecules and clinicopathological factors or clinical outcome. The 
      proportions of positive cases for EGFR, VEGF, and HER2 overexpression were 27.4, 
      53.8, and 0.9% in intrahepatic cholangiocarcinoma (IHCC), and 19.2, 59.2, and 
      8.5% in extrahepatic cholangiocarcinoma (EHCC), respectively. 
      Clinicopathologically, EGFR overexpression was associated with macroscopic type 
      (P=0.0120), lymph node metastasis (P=0.0006), tumour stage (P=0.0424), lymphatic 
      vessel invasion (P=0.0371), and perineural invasion (P=0.0459) in EHCC, and VEGF 
      overexpression with intrahepatic metastasis (P=0.0224) in IHCC. Multivariate 
      analysis showed that EGFR expression was a significant prognostic factor (hazard 
      ratio (HR), 2.67; 95% confidence interval (CI), 1.52-4.69; P=0.0006) and also a 
      risk factor for tumour recurrence (HR, 1.89; 95% CI, 1.05-3.39, P=0.0335) in 
      IHCC. These results suggest that EGFR expression is associated with tumour 
      progression and VEGF expression may be involved in haematogenic metastasis in 
      cholangiocarcinoma.
FAU - Yoshikawa, D
AU  - Yoshikawa D
AD  - Cancer Genomics Project, National Cancer Center Research Institute, Tokyo, Japan.
FAU - Ojima, H
AU  - Ojima H
FAU - Iwasaki, M
AU  - Iwasaki M
FAU - Hiraoka, N
AU  - Hiraoka N
FAU - Kosuge, T
AU  - Kosuge T
FAU - Kasai, S
AU  - Kasai S
FAU - Hirohashi, S
AU  - Hirohashi S
FAU - Shibata, T
AU  - Shibata T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071218
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bile Duct Neoplasms/*genetics/mortality/pathology
MH  - *Bile Ducts, Intrahepatic/metabolism
MH  - Cholangiocarcinoma/*genetics/mortality/pathology
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - *Genes, erbB-1
MH  - *Genes, erbB-2
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Recurrence
MH  - Survival Analysis
MH  - Vascular Endothelial Growth Factor A/*genetics
PMC - PMC2361442
EDAT- 2007/12/19 09:00
MHDA- 2008/03/28 09:00
PMCR- 2009/01/29
CRDT- 2007/12/19 09:00
PHST- 2007/12/19 09:00 [pubmed]
PHST- 2008/03/28 09:00 [medline]
PHST- 2007/12/19 09:00 [entrez]
PHST- 2009/01/29 00:00 [pmc-release]
AID - 6604129 [pii]
AID - 10.1038/sj.bjc.6604129 [doi]
PST - ppublish
SO  - Br J Cancer. 2008 Jan 29;98(2):418-25. doi: 10.1038/sj.bjc.6604129. Epub 2007 Dec 
      18.